Zenlabs Ethica Limited (BOM:530697)

India flag India · Delayed Price · Currency is INR
19.71
-0.79 (-3.85%)
At close: Mar 9, 2026
-40.31%
Market Cap 142.18M
Revenue (ttm) 493.24M
Net Income (ttm) -18.46M
Shares Out 6.51M
EPS (ttm) -2.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,175
Average Volume 2,447
Open 20.30
Previous Close 20.50
Day's Range 19.02 - 22.00
52-Week Range 18.00 - 39.20
Beta -1.04
RSI 45.61
Earnings Date May 12, 2026

About Zenlabs Ethica

Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is... [Read more]

Industry Drugs, Drug Proprietaries, and Druggists' Sundries
Founded 1993
Employees 65
Stock Exchange Bombay Stock Exchange
Ticker Symbol 530697
Full Company Profile

Financial Performance

In fiscal year 2025, Zenlabs Ethica's revenue was 514.23 million, a decrease of -12.19% compared to the previous year's 585.63 million. Earnings were 2.69 million, a decrease of -36.09%.

Financial Statements

News

There is no news available yet.